Table 2.
Changes from baseline in CT and 18F-FLT PET parameters according to confirmed treatment response
| All subjects, n=25 |
Non-progressive disease, n=16 |
Progressive disease, n=9 |
P value* | |
| Changes between baseline and week 2 | ||||
| ΔSUVmax0-2, % | 6.0 (−58.3 to 120.2) | 2.1 (−58.3 to 50.9) | 16.8 (−34.8 to 120.2) | 0.075 |
| ΔPTV0-2, % | 29.0 (−90.7 to 813.2) | 12.5 (−90.7 to 241.9) | 101.3 (−27.0 to 813.2) | 0.066 |
| ΔTLP0-2, % | 31.9 (−94.8 to 821.3) | 12.7 (−94.8 to 223.2) | 81.6 (−15.9 to 821.3) | 0.045 |
| All subjects, n=22 |
Non-progressive disease, n=16 |
Progressive disease, n=6 |
P value* | |
| Changes between baseline and week 6 | ||||
| ΔSUVmax0-6, % | −3.4 (-72.3 to 88.1) | −17.5 (-72.3 to 17.3) | 26.3 (-34.8 to 88.1) | 0.020 |
| ΔPTV0-6, % | −31.2 (−96.9 to 2528.1) | −54.7 (−96.9 to 67.1) | 95.0 (−23.9 to 2528.2) | 0.0017 |
| ΔTLP0-6, % | −24.9 (−97.1 to 3075.2) | −58.1 (−97.1 to 66.8) | 123.2 (−19.2 to 3075.2) | 0.0022 |
*P values compare the non-progressive and progressive disease groups.
18F-FLT, 3′-deoxy-3′-[18F]-fluorothymidine; PET, positron emission tomography; PTV, proliferative tumor volume; SUV, standardized uptake value; TLP, total lesion proliferation.